Immunomodulation in Pediatric Asthma

Frontiers in Pediatrics

article

Amelia Licari¹  Sara Manti²  Riccardo Castagnoli¹  Alessia Marseglia¹  Thomas Foiadelli¹  Ilaria Brambilla¹  Gian Luigi Marseglia¹ 

[1] Department of Pediatrics, University of Pavia;Unit of Pediatric Genetics and Immunology, Department of Pediatrics, University of Messina;Department of Clinical and Experimental Medicine, University of Catania

关键词: asthma;    children;    endotypes;    biologics;    treatment;    omalizumab;    mepolizumab;   

DOI  :  10.3389/fped.2019.00289

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Childhood asthma is actually defined as a heterogeneous disease, including different clinical variants and partially sharing similar immune mechanisms. Asthma management is mainly focused on maintaining the control of the disease and reducing the risk of adverse outcomes. Most children achieve good control with standard therapies, such as low doses of inhaled corticosteroids (ICS) and/or one or more controller. These medications are targeted to suppress bronchial inflammation and to restore airway responsiveness. However, they are not disease-modifying and do not specifically target inflammatory pathways of asthma; in addition, they are not significantly effective in patients with severe uncontrolled asthma. The aim of this review is to update knowledge on current and novel therapeutic options targeted to immunomodulate inflammatory pathways underlying pediatric asthma, with particular reference on biologic therapies.

【 授权许可】

CC BY